Study of EB 1089 in Advanced Cancer Patients
Author Information
Author(s): T Gulliford, J English, KW Colston, P Menday, S MolDer, RC Coombes
Primary Institution: Cancer Research Campaign Laboratories, Department of Cancer Medicine, Imperial College School of Medicine
Hypothesis
Does the vitamin D analogue EB 1089 have a lower calcaemic effect while providing anti-tumour activity in patients with advanced breast and colorectal cancer?
Conclusion
EB 1089 was well tolerated, but no significant anti-tumour responses were observed in patients with advanced cancer.
Supporting Evidence
- EB 1089 was given to 36 patients with advanced breast and colorectal cancer.
- Hypercalcaemia was seen in all patients receiving the highest dose of EB 1089.
- Six patients showed stabilization of disease after treatment.
Takeaway
Doctors tested a new medicine called EB 1089 on sick people to see if it could help their cancer without making their calcium levels too high, but it didn't work as well as they hoped.
Methodology
The study was a single-centre, open-label, non-controlled trial with sequential dose allocation.
Limitations
The study did not observe any clear anti-tumour effects, and all patients had previously received multiple anti-cancer therapies.
Participant Demographics
{"male":8,"female":28,"breast_cancer":25,"colon_cancer":11}
Statistical Information
P-Value
{"urine_calcium":0.0001,"serum_corrected_calcium":0.027,"serum_parathyroid_hormone":0.0001,"serum_creatinine":0.024}
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website